Pulmonary NTM | Alveolitis/pneumonitis | Bronchiectasis | Coccidioidomycosis | COPD | CF | Histoplasmosis | IPF | Neoplasm | Non-HIV immunodeficiency | Sarcoidosis | TB | |
Subjects | 189 | 2 | 112 | 1 | 420 | 9 | 3 | 2 | 44 | 15 | 9 | 78 |
Macrolide, ethambutol, rifamycin (optional aminoglycoside)# | 72 (38) | 0 (0) | 21 (19) | 0 (0) | 88 (21) | 3 (33) | 1 (33) | 0 (0) | 7 (16) | 5 (33) | 2 (22) | 35 (45) |
Macrolide monotherapy¶ | 16 (8) | 1 (50) | 22 (20) | 0 (0) | 66 (16) | 0 (0) | 0 (0) | 0 (0) | 12 (27) | 3 (20) | 0 (0) | 0 (0) |
Macrolide, quinolone¶ | 14 (7) | 0 (0) | 12 (11) | 0 (0) | 38 (9) | 1 (11) | 0 (0) | 0 (0) | 4 (9) | 0 (0) | 2 (22) | 1 (1) |
Macrolide, rifamycin¶ | 6 (3) | 1 (50) | 3 (3) | 0 (0) | 6 (1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (1) |
Macrolide, amikacin+ | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Macrolide, linezolid+ | 1 (1) | 0 (0) | 0 (0) | 0 (0) | 7 (2) | 0 (0) | 0 (0) | 0 (0) | 1 (2) | 0 (0) | 0 (0) | 0 (0) |
Macrolide, other+ | 28 (15) | 0 (0) | 8 (7) | 0 (0) | 37 (9) | 1 (11) | 0 (0) | 0 (0) | 2 (5) | 0 (0) | 1 (11) | 14 (18) |
Ethambutol, rifamycin§ | 4 (2) | 0 (0) | 1 (1) | 0 (0) | 11 (3) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 9 (12) |
Quinolone-based§ | 42 (22) | 0 (0) | 43 (38) | 1 (100) | 159 (38) | 2 (22) | 1 (33) | 2 (100) | 16 (36) | 5 (33) | 4 (44) | 1 (33) |
Aminoglycoside-based§ | 3 (2) | 0 (0) | 0 (0) | 0 (0) | 1 (0) | 2 (22) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Linezolid-based§ | 3 (2) | 0 (0) | 2 (2) | 0 (0) | 6 (1) | 0 (0) | 1 (33) | 0 (0) | 2 (5) | 2 (13) | 0 (0) | 0 (0) |
Data are presented as n or n (%). NTM: nontuberculous mycobacteria; COPD: chronic obstructive pulmonary disease; CF: cystic fibrosis; IPF: idiopathic pulmonary fibrosis; TB: tuberculosis. #: treatment regimens meeting American Thoracic Society/Infectious Disease Society of America guidelines; ¶: treatment regimens that potentially promote macrolide resistance; +: treatment regiments that are of unknown clinical significance; §: treatment regimens that do not include macrolides.